

## Highlights of This Issue 777

### RESEARCH ARTICLES

- 779 **Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma**  
Christina K. Augustine, Sin-Ho Jung, Insuk Sohn, Jin Soo Yoo, Yasunori Yoshimoto, John A. Olson, Jr., Henry S. Friedman, Francis Ali-Osman, and Douglas S. Tyler
- 791 **Vinblastine Induces Acute, Cell Cycle Phase-Independent Apoptosis in Some Leukemias and Lymphomas and Can Induce Acute Apoptosis in Others when Mcl-1 Is Suppressed**  
Bethany L. Salerni, Darcy J. Bates, Tina C. Albershardt, Christopher H. Lowrey, and Alan Eastman
- 803 **RelB-Dependent Differential Radiosensitization Effect of STI571 on Prostate Cancer Cells**  
Yong Xu, Fang Fang, Yulan Sun, Daret K. St. Clair, and William H. St. Clair
- 813 **Inhibition of Aldose Reductase Prevents Growth Factor-Induced G<sub>1</sub>-S Phase Transition through the AKT/Phosphoinositide 3-Kinase/E2F-1 Pathway in Human Colon Cancer Cells**  
Kota V. Ramana, Ravinder Tammali, and Satish K. Srivastava
- 825 **Phospholipase A<sub>2</sub> Activity of Peroxiredoxin 6 Promotes Invasion and Metastasis of Lung Cancer Cells**  
Jin-Nyoung Ho, Seung Bum Lee, Seung-Sook Lee, Sung Hwan Yoon, Ga Young Kang, Sang-Gu Hwang, and Hong-Duck Um
- 833  **$\beta$ -Ionone Enhances TRAIL-Induced Apoptosis in Hepatocellular Carcinoma Cells through Sp1-Dependent Upregulation of DR5 and Downregulation of NF- $\kappa$ B Activity**  
Mun-Ock Kim, Dong-Oh Moon, Chang-Hee Kang, Taeg Kyu Kwon, Yung Hyun Choi, and Gi-Young Kim
- 844 **SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2**  
Barrie Peck, Chun-Yuan Chen, Ka-Kei Ho, Paolo Di Fruscia, Stephen S. Myatt, R. Charles Coombes, Matthew J. Fuchter, Chwan-Deng Hsiao, and Eric W.-F. Lam
- 856 **Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins**  
Sahdeo Prasad, Jayaraj Ravindran, Bokyung Sung, Manoj K. Pandey, and Bharat B. Aggarwal
- 869 **Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species**  
Margarita I. Todorova, Anne-Laure Larroque, Sabine Dauphin-Pierre, You-Qiang Fang, and Bertrand J. Jean-Claude
- 883 **PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy**  
Jitesh P. Jani, Joel Arcari, Vincent Bernardo, Samit K. Bhattacharya, David Briere, Bruce D. Cohen, Kevin Coleman, James G. Christensen, Erling O. Emerson, Amy Jakowski, Kenneth Hook, Gerrit Los, James D. Moyer, Ingrid Pruumboom-Brees, Leslie Pustilnik, Ann Marie Rossi, Stefan J. Steyn, Chunyan Su, Konstantinos Tsaparikos, Donn Wishka, Kwansik Yoon, and John L. Jakubczak
- 895 **Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer Cells**  
Diarmuid M. Moran and Carl G. Maki
- 906 **Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800**  
Andrew J. Massey, Joseph Schoepfer, Paul A. Brough, Josef Brueggen, Patrick Chène, Martin J. Drysdale, Ulrike Pfaar, Thomas Radimerski, Stephan Ruetz, Alain Schweitzer, Mike Wood, Carlos Garcia-Echeverria, and Michael Rugaard Jensen

- 920 **AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples**  
Matthew S. Squires, Laurence Cooke, Victoria Lock, Wenqing Qi, E. Jonathan Lewis, Neil T. Thompson, John F. Lyons, and Daruka Mahadevan
- 929 **ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain**  
Jia-Jean Yiin, Bo Hu, Paul A. Schornack, Raghvendra S. Sengar, Kun-wei Liu, Haizhong Feng, Frank S. Lieberman, Shih-Hwa Chiou, Jann N. Sarkaria, Erik C. Wiener, Hsin-I Ma, and Shi-Yuan Cheng
- 942 **Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells**  
Rekha Rao, Srilatha Nalluri, Ravindra Kolhe, Yonghua Yang, Warren Fiskus, Jianguang Chen, Kyungsoo Ha, Kathleen M. Buckley, Ramesh Balusu, Veena Coothankandaswamy, Atul Joshi, Peter Atadja, and Kapil N. Bhalla
- 953 **Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3**  
Fan Yang, Christine Brown, Ralf Buettner, Michael Hedvat, Renate Starr, Anna Scuto, Anne Schroeder, Michael Jensen, and Richard Jove
- 963 **Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma**  
Diana Cirstea, Teru Hideshima, Scott Rodig, Loredana Santo, Samantha Pozzi, Sonia Vallet, Hiroshi Ikeda, Giulia Perrone, Kishan Patel, Neil Desai, Peter Sportelli, Shweta Kapoor, Shireen Vali, Siddhartha Mukherjee, Nikhil C. Munshi, Kenneth C. Anderson, and Noopur Raje
- 976 **Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor**  
Robert Mallon, Irwin Hollander, Larry Feldberg, Judy Lucas, Veronica Soloveva, Aranapakam Venkatesan, Christoph Dehnhardt, Efren Delos Santos, Zecheng Chen, Osvaldo dos Santos, Semiramis Ayrál-Kaloustian, and Jay Gibbons
- 985 **Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer**  
William M. Merritt, Alpa M. Nick, Amy R. Carroll, Chunhua Lu, Koji Matsuo, Melissa Dumble, Nicholas Jennings, ShuYun Zhang, Yvonne G. Lin, Whitney A. Spannuth, Aparna A. Kamat, Rebecca L. Stone, Mian M.K. Shahzad, Robert L. Coleman, Rakesh Kumar, and Anil K. Sood
- 996 **Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer**  
Kae Hashimoto, Shan Man, Ping Xu, William Cruz-Munoz, Terence Tang, Rakesh Kumar, and Robert S. Kerbel
- 1007 **Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer**  
Ahmed El-Gazzar, Paul Perco, Eva Eckelhart, Mariam Anees, Veronika Sexl, Bernd Mayer, Yanxin Liu, Wolfgang Mikulits, Reinhard Horvat, Thomas Pangerl, Dexian Zheng, and Michael Krainer
- 1019 **Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a <sup>68</sup>Ga- and <sup>18</sup>F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts**  
Rafke Schoffelen, Robert M. Sharkey, David M. Goldenberg, Gerben Franssen, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, Peter Laverman, Jonathan A. Disselhorst, Annemarie Eek, Winette T.A. van der Graaf, Wim J.G. Oyen, and Otto C. Boerman
- 1028 **A Molecularly Targeted Theranostic Probe for Ovarian Cancer**  
Wenxue Chen, Rizia Bardhan, Marc Bartels, Carlos Perez-Torres, Robia G. Pautler, Naomi J. Halas, and Amit Joshi

- 1039 | **Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38**  
Neal Luther, Nai-Kong Cheung, Eleni P. Souliopoulos, Ioannis Karempelas, Daniel Bassiri, Mark A. Edgar, Hong-fen Guo, Ira Pastan, Philip H. Gutin, and Mark M. Souweidane
- 1047 | **Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2**  
Olaf H. Temmink, Irene V. Bijnsdorp, Henk-Jan Prins, Nienke Losekoot, Auke D. Adema, Kees Smid, Richard J. Honeywell, Bauke Ylstra, Paul P. Eijk, Masakazu Fukushima, and Godefridus J. Peters
- 1058 | **Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue**  
Swati S. More, Shuanglian Li, Sook Wah Yee, Ligong Chen, Zhidong Xu, David M. Jablons, and Kathleen M. Giacomini

## LETTERS TO THE EDITOR

- 1070 | **Erythropoietin Receptor in Ovarian Cancer Cells – Letter**  
Susan E. Swift, Steve Elliott, Angus M. Sinclair, and C. Glenn Begley
- 1071 | **Erythropoietin and Ovarian Cancer – Response**  
Peter Solár, Ján Koval, Jaromír Mikeš, Ján Kleban, Zuzana Solárová, Ján Lazúr, Ingrid Hodorová, Peter Fedoročko, and Arthur J. Sytkowski

## CORRECTION

- 1073 | **Correction: Tumor Necrosis Factor Deficiency Inhibits Mammary Tumorigenesis and a Tumor Necrosis Factor Neutralizing Antibody Decreases Mammary Tumor Growth in neu/erbB2 Transgenic Mice**

## ABOUT THE COVER

Immunofluorescent image of untreated A549 lung adenocarcinoma cells. A549 cells seeded on collagen coated coverslips were stained for focal adhesions (antivinculin antibody; green) and F-Actin stress fibers (rhodamine conjugated phalloidin; red). Nuclei were visualized by DAPI staining (blue). It was found that Nutlin 3, a small molecule inhibitor of MDM2, decreases F-actin stress fibers, focal adhesions and invasion in p53wt human cancer cells. For details, see article by Moran and Maki on page 895.

